{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T09:39:41Z","timestamp":1788514781262,"version":"build-2803163510"},"reference-count":41,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T00:00:00Z","timestamp":1672358400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"crossref","award":["JP19dm0908001"],"award-info":[{"award-number":["JP19dm0908001"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000646","name":"Japan Society for the Promotion of Science London","doi-asserted-by":"publisher","award":["19K08037"],"award-info":[{"award-number":["19K08037"]}],"id":[{"id":"10.13039\/501100000646","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"crossref","award":["JP20dm0107162"],"award-info":[{"award-number":["JP20dm0107162"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100009619","name":"AMED","doi-asserted-by":"crossref","award":["JP21zf0127005"],"award-info":[{"award-number":["JP21zf0127005"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Research Committee of Central Nervous System Degenerative Diseases","award":["20FC1049"],"award-info":[{"award-number":["20FC1049"]}]},{"name":"Research Committee of Central Nervous System Degenerative Diseases","award":["20FC1049"],"award-info":[{"award-number":["20FC1049"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Patients with Parkinson\u2019s disease (PD) often suffer from sleep disturbances, including excessive daytime sleepiness (EDS) and rapid eye movement sleep behavior disorder (RBD). These symptoms are also experienced by patients with narcolepsy, which is characterized by orexin neuronal loss. In PD, a decrease in orexin neurons is observed pathologically, but the association between sleep disturbance in PD and cerebrospinal fluid (CSF) orexin levels is still unclear. This study aimed to clarify the role of orexin as a biomarker in patients with PD. CSF samples were obtained from a previous cohort study conducted between 2015 and 2020. We cross-sectionally and longitudinally examined the association between CSF orexin levels, sleep, and clinical characteristics. We analyzed 78 CSF samples from 58 patients with PD and 21 samples from controls. CSF orexin levels in patients with PD (median = 272.0 [interquartile range = 221.7\u2013334.5] pg\/mL) were lower than those in controls (352.2 [296.2\u2013399.5] pg\/mL, p = 0.007). There were no significant differences in CSF orexin levels according to EDS, RBD, or the use of dopamine agonists. Moreover, no significant correlation was observed between CSF orexin levels and clinical characteristics by multiple linear regression analysis. Furthermore, the longitudinal changes in orexin levels were also not correlated with clinical characteristics. This study showed decreased CSF orexin levels in patients with PD, but these levels did not show any correlation with any clinical characteristics. Our results suggest the limited efficacy of CSF orexin levels as a biomarker for PD, and that sleep disturbances may also be affected by dysfunction of the nervous system other than orexin, or by dopaminergic treatments in PD. Understanding the reciprocal role of orexin among other neurotransmitters may provide a better treatment strategy for sleep disturbance in patients with PD.<\/jats:p>","DOI":"10.1371\/journal.pone.0279747","type":"journal-article","created":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T18:53:49Z","timestamp":1672426429000},"page":"e0279747","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":16,"title":["Decreased cerebrospinal fluid orexin levels not associated with clinical sleep disturbance in Parkinson\u2019s disease: A retrospective study"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3118-547X","authenticated-orcid":true,"given":"Takuya","family":"Ogawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7170-0758","authenticated-orcid":true,"given":"Yuta","family":"Kajiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Ishido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9458-5713","authenticated-orcid":true,"given":"Shigeru","family":"Chiba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3753-4140","authenticated-orcid":true,"given":"Gajanan S.","family":"Revankar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohito","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seira","family":"Taniguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Kanbayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kensuke","family":"Ikenaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideki","family":"Mochizuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2022,12,30]]},"reference":[{"key":"pone.0279747.ref001","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11940-017-0461-6","article-title":"Treatment of sleep dysfunction in Parkinson\u2019s disease","volume":"19","author":"AW Amara","year":"2017","journal-title":"Curr Treat Options Neurol"},{"key":"pone.0279747.ref002","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1038\/nrneurol.2014.206","article-title":"\u2018The clocks that time us\u2019\u2014circadian rhythms in neurodegenerative disorders","volume":"10","author":"A Videnovic","year":"2014","journal-title":"Nat Rev Neurol"},{"key":"pone.0279747.ref003","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/sleep\/27.5.967","article-title":"Daytime sleepiness and alertness in patients with Parkinson disease","volume":"27","author":"S Stevens","year":"2004","journal-title":"Sleep"},{"key":"pone.0279747.ref004","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/j.smrv.2005.03.004","article-title":"Symptomatic narcolepsy, cataplexy and hypersomnia, and their implications in the hypothalamic hypocretin\/orexin system","volume":"9","author":"S Nishino","year":"2005","journal-title":"Sleep Med Rev"},{"key":"pone.0279747.ref005","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1212\/WNL.58.3.498","article-title":"Normal hypocretin-1 levels in Parkinson\u2019s disease patients with excessive daytime sleepiness","volume":"58","author":"S Overeem","year":"2002","journal-title":"Neurology"},{"key":"pone.0279747.ref006","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1093\/brain\/awm090","article-title":"Hypocretin (orexin) loss in Parkinson\u2019s disease","volume":"130","author":"R Fronczek","year":"2007","journal-title":"Brain"},{"key":"pone.0279747.ref007","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1093\/brain\/awm097","article-title":"Hypocretin (orexin) cell loss in Parkinson\u2019s disease","volume":"130","author":"TC Thannickal","year":"2007","journal-title":"Brain"},{"key":"pone.0279747.ref008","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1097\/WNR.0b013e32833bfb7c","article-title":"Reduced hypocretin (orexin) levels in dementia with Lewy bodies","volume":"21","author":"S Lessig","year":"2010","journal-title":"NeuroReport"},{"key":"pone.0279747.ref009","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1212\/01.WNL.0000078194.53210.48","article-title":"Low levels of ventricular CSF orexin\/hypocretin in advanced PD","volume":"61","author":"X Drouot","year":"2003","journal-title":"Neurology"},{"key":"pone.0279747.ref010","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3233\/JAD-2012-111655","article-title":"Altered CSF orexin and \u03b1-synuclein levels in dementia patients","volume":"29","author":"M Wennstr\u00f6m","year":"2012","journal-title":"J Alzheimers Dis"},{"key":"pone.0279747.ref011","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1159\/000509585","article-title":"Cerebrospinal fluid hypocretin and nightmares in dementia syndromes","volume":"11","author":"LM Trotti","year":"2021","journal-title":"Dement Geriatr Cogn Dis Extra"},{"key":"pone.0279747.ref012","doi-asserted-by":"crossref","first-page":"765701","DOI":"10.3389\/fendo.2021.765701","article-title":"Orexin-A in patients With lewy body disease: A systematic review and meta-analysis","volume":"12","author":"J Gan","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"pone.0279747.ref013","doi-asserted-by":"crossref","first-page":"826013","DOI":"10.3389\/fneur.2022.826013","article-title":"Cerebrospinal fluid TNF-\u03b1 and orexin in patients With Parkinson\u2019s disease and rapid eye movement sleep behavior disorder","volume":"13","author":"Y Yuan","year":"2022","journal-title":"Front Neurol"},{"key":"pone.0279747.ref014","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.clineuro.2008.11.007","article-title":"Cerebrospinal fluid-orexin levels and sleep attacks in four patients with Parkinson\u2019s disease","volume":"111","author":"H Asai","year":"2009","journal-title":"Clin Neurol Neurosurg"},{"key":"pone.0279747.ref015","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.jns.2006.08.004","article-title":"CSF orexin levels of Parkinson\u2019s disease, dementia with Lewy bodies, progressive supranuclear palsy and corticobasal degeneration","volume":"250","author":"K Yasui","year":"2006","journal-title":"J Neurol Sci"},{"key":"pone.0279747.ref016","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1093\/brain\/awp263","article-title":"Cerebrospinal hypocretin, daytime sleepiness and sleep architecture in Parkinson\u2019s disease dementia","volume":"132","author":"Y Compta","year":"2009","journal-title":"Brain"},{"key":"pone.0279747.ref017","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1159\/000079749","article-title":"Normal CSF hypocretin-1 (orexin A) levels in dementia with Lewy bodies associated with excessive daytime sleepiness","volume":"52","author":"CR Baumann","year":"2004","journal-title":"Eur Neurol"},{"key":"pone.0279747.ref018","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1111\/j.1468-1331.2010.02954.x","article-title":"Cerebrospinal fluid hypocretin levels are normal in idiopathic REM sleep behaviour disorder","volume":"17","author":"KN Anderson","year":"2010","journal-title":"Eur J Neurol"},{"key":"pone.0279747.ref019","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1111\/psyg.12618","article-title":"Association between cerebrospinal fluid orexin A level and severity of rapid eye movement sleep behaviour disorder in dementia with Lewy bodies","volume":"21","author":"Y Inagawa","year":"2021","journal-title":"Psychogeriatrics"},{"key":"pone.0279747.ref020","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.neures.2010.08.005","article-title":"An anti-Parkinson drug ropinirole depletes orexin from rat hypothalamic slice culture","volume":"68","author":"S Michinaga","year":"2010","journal-title":"Neurosci Res"},{"key":"pone.0279747.ref021","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1111\/j.1365-2869.2012.01027.x","article-title":"Progressive dopamine and hypocretin deficiencies in Parkinson\u2019s disease: is there an impact on sleep and wakefulness?","volume":"21","author":"M Wienecke","year":"2012","journal-title":"J Sleep Res"},{"key":"pone.0279747.ref022","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.parkreldis.2021.06.007","article-title":"Neural networks associated with quality of life in patients with Parkinson\u2019s disease","volume":"89","author":"T Nakano","year":"2021","journal-title":"Parkinsonism Relat Disord"},{"key":"pone.0279747.ref023","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41531-021-00237-z","article-title":"Decreased frontotemporal connectivity in patients with Parkinson\u2019s disease experiencing face pareidolia","volume":"7","author":"Y Kajiyama","year":"2021","journal-title":"npj Parkinsons Dis"},{"key":"pone.0279747.ref024","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","article-title":"A new method for measuring daytime sleepiness: the Epworth Sleepiness Scale","volume":"14","author":"MW Johns","year":"1991","journal-title":"Sleep"},{"key":"pone.0279747.ref025","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1002\/mds.21740","article-title":"The REM sleep behavior disorder screening questionnaire\u2014a new diagnostic instrument","volume":"22","author":"K Stiasny-Kolster","year":"2007","journal-title":"Mov Disord"},{"key":"pone.0279747.ref026","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1212\/WNL.17.5.427","article-title":"Parkinsonism: onset, progression and mortality","volume":"17","author":"MM Hoehn","year":"1967","journal-title":"Neurology"},{"key":"pone.0279747.ref027","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1002\/mds.22340","article-title":"Movement Disorder Society-Sponsored Revision of the Unified Parkinson\u2019s Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results","volume":"23","author":"CG Goetz","year":"2008","journal-title":"Mov Disord"},{"key":"pone.0279747.ref028","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1002\/mds.23834","article-title":"Health-related quality-of-life scales in Parkinson\u2019s disease: critique and recommendations","volume":"26","author":"P Martinez-Martin","year":"2011","journal-title":"Mov Disord"},{"key":"pone.0279747.ref029","first-page":"189","article-title":"\"Mini-mental state\". A practical method for grading the cognitive state of patients for the clinician","volume":"12","author":"MF Folstein","year":"1975","journal-title":"J Psychiatr Res"},{"key":"pone.0279747.ref030","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1212\/WNL.55.11.1621","article-title":"The FAB: a Frontal Assessment Battery at bedside","volume":"55","author":"B Dubois","year":"2000","journal-title":"Neurology"},{"key":"pone.0279747.ref031","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1002\/mds.20153","article-title":"Assessment of autonomic dysfunction in Parkinson\u2019s disease: the SCOPA-AUT","volume":"19","author":"M Visser","year":"2004","journal-title":"Mov Disord"},{"key":"pone.0279747.ref032","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1300\/J018v05n01_09","article-title":"9\/Geriatric Depression Scale (GDS): recent evidence and development of a shorter version","volume":"5","author":"JA Yesavage","year":"1986","journal-title":"Clin Gerontol"},{"key":"pone.0279747.ref033","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1161\/01.STR.24.11.1625","article-title":"Apathy following cerebrovascular lesions","volume":"24","author":"SE Starkstein","year":"1993","journal-title":"Stroke"},{"key":"pone.0279747.ref034","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1001\/archneur.59.10.1553","article-title":"The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias","volume":"59","author":"E Mignot","year":"2002","journal-title":"Arch Neurol"},{"key":"pone.0279747.ref035","doi-asserted-by":"crossref","first-page":"1872","DOI":"10.1002\/acn3.50833","article-title":"Biomarkers for REM sleep behavior disorder in idiopathic and narcoleptic patients","volume":"6","author":"E Antelmi","year":"2019","journal-title":"Ann Clin Transl Neurol"},{"issue":"Suppl 3","key":"pone.0279747.ref036","doi-asserted-by":"crossref","first-page":"S101","DOI":"10.1016\/S1353-8020(09)70792-8","article-title":"Sleepiness in Parkinson\u2019s disease","volume":"15","author":"I Arnulf","year":"2009","journal-title":"Parkinsonism Relat Disord"},{"key":"pone.0279747.ref037","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/nrn2092","article-title":"The neural circuit of orexin (hypocretin): maintaining sleep and wakefulness","volume":"8","author":"T. Sakurai","year":"2007","journal-title":"Nat Rev Neurosci"},{"key":"pone.0279747.ref038","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.parkreldis.2009.08.007","article-title":"A timeline for Parkinson\u2019s disease","volume":"16","author":"CH Hawkes","year":"2010","journal-title":"Parkinsonism Relat Disord"},{"key":"pone.0279747.ref039","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1016\/S0014-4886(03)00388-1","article-title":"Relationship between CSF hypocretin levels and hypocretin neuronal loss","volume":"184","author":"D Gerashchenko","year":"2003","journal-title":"Exp Neurol"},{"key":"pone.0279747.ref040","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jocn.2004.09.021","article-title":"Cerebrospinal fluid orexin in aneurysmal subarachnoid haemorrhage\u2014a pilot study","volume":"12","author":"BT Ang","year":"2005","journal-title":"J Clin Neurosci"},{"key":"pone.0279747.ref041","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1097\/AJP.0b013e318156d961","article-title":"Analysis of cerebrospinal fluid inflammatory mediators in chronic complex regional pain syndrome related dystonia","volume":"24","author":"AG Munts","year":"2008","journal-title":"Clin J Pain"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0279747","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,30]],"date-time":"2022-12-30T18:54:13Z","timestamp":1672426453000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0279747"}},"subtitle":[],"editor":[{"given":"Claudio","family":"Liguori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2022,12,30]]},"references-count":41,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,12,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0279747","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,30]]}}}